The DOI matches its Crossref record; 255 of the 255 references it cites were found in a registry or an index.
The Endocannabinoid System and Pain
Open accessAbstract
The therapeutic potential of cannabinoids has been the topic of extensive investigation following the discovery of cannabinoid receptors and their endogenous ligands. Cannabinoid receptors and their endogenous ligands are present at supraspinal, spinal and peripheral levels. Cannabinoids suppress behavioral responses to noxious stimulation and suppress nociceptive processing through activation of cannabinoid CB(1) and CB(2) receptor subtypes. Endocannabinoids, the brain's own cannabis-like substances, share the same molecular target as Delta(9)-tetrahydrocannabinol, the main psychoactive component in cannabis. Endocannabinoids serve as synaptic circuit breakers and regulate multiple physiological and pathological conditions, e.g. regulation of food intake, immunomodulation, inflammation, analgesia, cancer, addictive behavior, epilepsy and others. This review will focus on uncovering the roles of anandamide and 2-arachidonoylglycerol, the two best characterized endocannabinoids identified to date, in controlling nociceptive responding. The roles of anandamide and 2-arachidonoylglycerol, released under physiological conditions, in modulating nociceptive responding at different levels of the neuraxis will be emphasized in this review. Effects of modulation of endocannabinoid levels through inhibition of endocannabinoid hydrolysis and uptake is also compared with effects of exogenous administration of synthetic endocannabinoids in acute, inflammatory and neuropathic pain models. Finally, the therapeutic potential of the endocannabinoid signaling system is discussed in the context of identifying novel pharmacotherapies for the treatment of pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cannabinoidinduced antinociception is reported in a variety of preclinical inflammatory pain models (Table 2; also see a review by Guindon and Hohmann, 2009), including intraplantar injection (that is, into the ventral footpad) of the seaweed extract carrageenan, and the Gram-negative bacterial-derived endotoxin lipopolysaccharide (LPS).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Guindon and Hohmann, 2009
In the citing paper
“Using complementary genetic and pharmacological approaches, distinct components of the endocannabinoid system (ie, receptors and endocannabinoid-regulating enzymes) have emerged as promising targets to treat neuropathic pain (Table 5; for additional information, Guindon and Hohmann, 2009;Rahn and Hohmann, 2009).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Guindon and Hohmann, 2009
In the citing paper
“and supports a growing body of previous work in numerous contexts demonstrating the considerable potential of the endocannabinoid system as a target for the development of new therapies to alleviate pain [14,17].”
From Endocannabinoid involvement in endometriosis. (2010) · cites this paper as [17]
In the citing paper
“Although mechanisms by which the endocannabinoid system and exogenous cannabinoid agents act to influence pain are under intense study [14,17], little is known in the specific context of endometriosis-associated pain.”
From Endocannabinoid involvement in endometriosis. (2010) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–255 of 255
Sagar, D. R., Kendall, D. A., & Chapman, V. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.335 · Cited by 89
Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain
Jhaveri, M. D., Sagar, D. R., Elmes, S. J. R., Kendall, D. A., & Chapman, V. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-8007-7 · Cited by 89
Compton, D. R., & Martin, B. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37121-6 · Cited by 86
de Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega‐Gutiérrez, S., Fernández‐Ruíz, J., & Marzo, V. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.011 · Cited by 86
Palazzo, E., De Novellis, V., Petrosino, S., Marabese, I., Vita, D., Giordano, C., Di Marzo, V., Mangoni, G. S., Rossi, F., & Maione, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05086.x · Cited by 86 · cited 7×
“AEA and 2-AG are also increased in the spinal cord following induction of a neuropathic pain state produced by CCI of the sciatic nerve [140].”
BackgroundInfluentialHelyes, Z., Németh, J., Thán, M., Bölcskei, K., Pintér, E., & Szolcsányi, J. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00651-9 · Cited by 85
Selective Cannabinoid CB1Receptor Activation Inhibits Spinal Nociceptive Transmission In Vivo
Kelly, S., & Chapman, V. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.86.6.3061 · Cited by 84
Cannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain
Burns, T. L., & Ineck, J. R. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g217 · Cited by 84
Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception
Mason, D. J., Lowe, J. A., III, & Welch, S. P. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00479-3 · Cited by 83
Kostenis, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20092 · Cited by 83
Salio, C., Doly, S., Fischer, J., Franzoni, M. F., & Conrath, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00549-9 · Cited by 81
Strangman, N. M., & Walker, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.1.472 · Cited by 81
Welch, S. P., Dunlow, L. D., Patrick, G., & Razdan, R. K. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09617-x · Cited by 79
Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Reggio, P. H. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033454577 · Cited by 78
Suplita, R. L., Gutierrez, T., Fegley, D., Piomelli, D., & Hohmann, A. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.007 · Cited by 78
Self-citationAteş, M., Hamza, M., Seidel, K., Kotalla, C., Ledent, C. A., & Gühring, H. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02470.x · Cited by 77
Bisogno, T., Ortar, G., Petrosino, S., Morera, E., Palazzo, E., Nalli, M., Maione, S., & Marzo, V. D. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.10.007 · Cited by 76
Farquhar-Smith, W. P., & Rice, A. S. C. (2003) · Anesthesiology · doi:10.1097/00000542-200312000-00024 · Cited by 75
The therapeutic potential of novel cannabinoid receptors
Kreitzer, F. R., & Stella, N. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.01.005 · Cited by 75
Karbarz, M. J., Luo, L., Chang, L., Tham, C.-S., Palmer, J. A., Wilson, S. J., Wennerholm, M. L., Brown, S. M., Scott, B. P., Apodaca, R. L., et al. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31818c7cbd · Cited by 74
Bouaboula, M., Bianchini, L., McKenzie, F. R., Pouysségur, J., & Casellas, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00395-6 · Cited by 70
Ross, H., Gilmore, A. J., & Connor, M. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00072.x · Cited by 69
NewN-Arachidonoylserotonin Analogues with Potential “Dual” Mechanism of Action against Pain
Ortar, G., Cascio, M. G., PETROCELLIS, L. D., Morera, E., Rossi, F., Moriello, A. S., Nalli, M., de Novellis, V., Woodward, D. F., Maione, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070678q · Cited by 67
Sokal, D. M., Elmes, S. J. R., Kendall, D. A., & Chapman, V. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00195-3 · Cited by 67
Jin, X., Uyama, T., Wang, J., Okamoto, Y., Tonai, T., & Ueda, N. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.09.006 · Cited by 65
de Lago, E., Fernández‐Ruíz, J., Ortega‐Gutiérrez, S., Viso, A., López-Rodríguez, M. L., & Ramos, J. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01996-9 · Cited by 65
Ligresti, A., Cascio, M. G., Pryce, G., Kulasegram, S., Beletskaya, I., PETROCELLIS, L. D., Saha, B., Mahadevan, A., Visintin, C., Wiley, J. L., et al. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706418 · Cited by 65
Desroches, J., Guindon, J., Lambert, C., & Beaulieu, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.322 · Cited by 63
Self-citationGuindon, J., LoVerme, J., Léan, A. D., Piomelli, D., & Beaulieu, P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.08.045 · Cited by 59
Self-citationThe ligand that came from within
Piomelli, D. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01602-3 · Cited by 56
Russo, R., LoVerme, J., Rana, G. L., D’Agostino, G., Sasso, O., Calignano, A., & Piomelli, D. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.007 · Cited by 55
Novel inhibitors of fatty acid amide hydrolase
Sit, S. Y., Conway, C., Bertekap, R., Xie, K., Bourin, C., Burris, K., & Deng, H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.009 · Cited by 52
Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase
Haller, V. L., Stevens, D. L., & Welch, S. P. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.08.005 · Cited by 46
Phosphoinositide-specific phospholipase C (PI-PLC) β1 and nuclear lipid-dependent signaling
Cocco, L., Faenza, I., Fiume, R., Billi, A. M., Gilmour, R. S., & Manzoli, F. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.03.001 · Cited by 45
Costa, B., Vailati, S., & Colleoni, M. (1999) · Behavioural Pharmacology · doi:10.1097/00008877-199905000-00009 · Cited by 44
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models
Mitchell, V. A., Greenwood, R., Jayamanne, A., & Vaughan, C. W. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04692.x · Cited by 43
La Rana, G., Russo, R., D'Agostino, G., Sasso, O., Raso, G. M., Iacono, A., Meli, R., Piomelli, D., & Calignano, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.021 · Cited by 42
Guindon, J., LoVerme, J., Piomelli, D., & Beaulieu, P. (2007) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000263278.05423.a3 · Cited by 38
Self-citationBrain TRPV1: a depressing TR(i)P down memory lane?
Marzo, V. D., Gobbi, G., & SZALLASI, A. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.004 · Cited by 37
The Role of the Endogenous Cannabinoid System in Peripheral Analgesia
Guindon, J., & Beaulieu, P. (2009) · Current Molecular Pharmacology · doi:10.2174/1874467210902010134 · Cited by 37
Self-citationGuindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.41 · Cited by 37
Self-citationHonoré, P., Chapman, V., Buritova, J., et al. (1995) · Brain Research · doi:10.1016/0006-8993(95)01148-x · Cited by 35
Hohmann, A. G., Tsou, K., & Walker, J. M. (1999) · PubMed · Cited by 35
Self-citationMaione, S., Morera, E., Marabese, I., Ligresti, A., Luongo, L., Ortar, G., & Marzo, V. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.308 · Cited by 33
Suplita, R. L., Eisenstein, S. A., Neely, M. H., Moise, A. M., & Hohmann, A. G. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.006 · Cited by 33
Self-citationEvaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice
Wiley, J. L., Razdan, R. K., & Martin, B. R. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.08.017 · Cited by 33
Uhlenbrock, K., Huber, J., Ardati, A., et al. (2003) · Cellular Physiology and Biochemistry · doi:10.1159/000070251 · Cited by 31
Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH)
Timmons, A., Seierstad, M. J., Apodaca, R. L., Epperson, M., Pippel, D., Brown, S. M., Chang, L., Scott, B. P., Webb, M., Chaplan, S. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.091 · Cited by 29
Raffa, R. B., Stone, D. J., & Hipp, S. J. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00096-8 · Cited by 20
Johanek, L. M., & Simone, D. A. (2004) · Journal of Neurophysiology · doi:10.1152/jn.00673.2004 · Cited by 19
Hasanein, P., Shahidi, ., Komaki, A., & Mirazi, N. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.061 · Cited by 14
Berkenbosch, A. (1967) · PubMed · Cited by 11
Hasanein, P., & Javanmardi, K. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00626.x · Cited by 10
A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity
Magrioti, V., Naxakis, G., Hadjipavlou‐Litina, D., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.039 · Cited by 8
The antinociceptive interaction of anandamide and adenosine at the spinal level
Tuboly, G., Kékesi, G., Nagy, E., Benedek, G., & Horváth, G. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.010 · Cited by 3
Flagged first, then by citations
Research works printed but not linked: 3
- [1]Abel EL Marijuana: The first twelve thousand years 1980 New York Plenum Press
- [24]Herkenham M Pertwee RG Localization of cannabinoid receptors in brain and periphery Cannabinoid receptors 1995 London Academic Press 145 166
- [113]Guindon J Hohmann AG Handbook of Neuroscience for the Neural and Behavioral Sciences Bernston Gary G Cacioppo John T Pain: Mechanisms and Measurement 2009 New Jersey John H. Wiley & Sons in press
Cited by
Sorted by citations
Slominski (2012) · doi:10.1007/978-3-642-19683-6_1 · Cited by 461
Cannabinoids for treatment of chronic non‐cancer pain; a systematic review of randomized trials
Lynch, M. E., & Campbell, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03970.x · Cited by 397
Borsook, D., Upadhyay, J., Chudler, E. H., & Becerra, L. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-27 · Cited by 326
Jennings, E. M., Okine, B. N., Roche, M., & Finn, D. P. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.003 · Cited by 318
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Metadata
- Authors
- Guindon, J., & Hohmann, A.
- Affiliations
- University of Georgia (US)
- Corresponding author
- Hohmann, Andrea
- ORCID
- Hohmann, Andrea
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-12-01
- Volume
- 8
- Issue
- 6
- Pages
- 403-421
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- PMC
- PMC2834283
- OpenAlex
- W2054998310
- Cited by
- 476
- References
- 255
- Citations by year
- 2026: 21 · 2025: 19 · 2024: 36 · 2023: 27 · 2022: 41 · 2021: 38 · 2020: 23 · 2019: 25 · 2018: 33 · 2017: 27 · 2016: 23 · 2015: 23 · 2014: 39 · 2013: 28 · 2012: 36
- FWCI
- 17.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- CNS & Neurological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (DA022478, DA-022702, R21DA022478, R01DA021644, R21DA022702, DA021644)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- endocannabinoid system, pain, anandamide, 2-arachidonoylglycerol, cannabinoid receptors, CB1 receptor, CB2 receptor, nociception, analgesia, neuropathic pain, inflammatory pain, synthetic cannabinoids, pharmacological pain management
- MeSH terms
- Animals, Arachidonic Acids, Brain, Glycerides, Humans, Pain, Receptors, Cannabinoid, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
